Brokerages Expect SAGE Therapeutics Inc (SAGE) Will Announce Earnings of -$2.04 Per Share
Equities analysts expect that SAGE Therapeutics Inc (NASDAQ:SAGE) will report earnings of ($2.04) per share for the current quarter, Zacks reports. Zero analysts have made estimates for SAGE Therapeutics’ earnings, with estimates ranging from ($2.35) to ($1.79). SAGE Therapeutics reported earnings of ($1.50) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 36%. The firm is expected to report its next quarterly earnings report on Thursday, February 22nd.
On average, analysts expect that SAGE Therapeutics will report full year earnings of ($7.42) per share for the current fiscal year, with EPS estimates ranging from ($7.73) to ($7.16). For the next fiscal year, analysts forecast that the business will post earnings of ($7.69) per share, with EPS estimates ranging from ($9.08) to ($6.43). Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that cover SAGE Therapeutics.
SAGE Therapeutics (NASDAQ:SAGE) last issued its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.97) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.98) by $0.01. The firm’s revenue for the quarter was up .0% compared to the same quarter last year.
Shares of SAGE Therapeutics (NASDAQ SAGE) traded down $2.95 on Friday, hitting $161.37. The stock had a trading volume of 344,500 shares, compared to its average volume of 607,061. SAGE Therapeutics has a fifty-two week low of $44.55 and a fifty-two week high of $173.36.
In related news, insider Albert Robichaud sold 60,000 shares of the stock in a transaction that occurred on Thursday, December 14th. The stock was sold at an average price of $159.43, for a total transaction of $9,565,800.00. Following the sale, the insider now directly owns 152,759 shares in the company, valued at approximately $24,354,367.37. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 6.10% of the stock is owned by corporate insiders.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. BlackRock Inc. boosted its position in SAGE Therapeutics by 5.9% in the 2nd quarter. BlackRock Inc. now owns 3,031,548 shares of the biopharmaceutical company’s stock valued at $241,431,000 after buying an additional 168,424 shares during the last quarter. Vanguard Group Inc. boosted its position in SAGE Therapeutics by 2.2% in the 2nd quarter. Vanguard Group Inc. now owns 2,749,954 shares of the biopharmaceutical company’s stock valued at $219,006,000 after buying an additional 58,679 shares during the last quarter. Bank of New York Mellon Corp boosted its position in SAGE Therapeutics by 36.5% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,710,027 shares of the biopharmaceutical company’s stock valued at $168,834,000 after buying an additional 724,494 shares during the last quarter. State Street Corp boosted its position in SAGE Therapeutics by 7.7% in the 2nd quarter. State Street Corp now owns 1,212,384 shares of the biopharmaceutical company’s stock valued at $96,558,000 after buying an additional 87,097 shares during the last quarter. Finally, Oak Ridge Investments LLC boosted its position in SAGE Therapeutics by 0.9% in the 3rd quarter. Oak Ridge Investments LLC now owns 736,709 shares of the biopharmaceutical company’s stock valued at $45,897,000 after buying an additional 6,835 shares during the last quarter. Hedge funds and other institutional investors own 95.33% of the company’s stock.
SAGE Therapeutics Company Profile
SAGE Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing and commercializing medicines to treat central nervous system (CNS) disorders. The Company’s lead product candidate, SAGE-547 is an intravenous formulation of allopregnanolone, a neurosteroid that acts as a synaptic and extrasynaptic modulator of the Gamma-Amino Butyric Acid-A (GABAA) receptor.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for SAGE Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SAGE Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.